Efficacy and Safety Study of Autonomic Nerve Modulation (ANM) in Subjects With Moderate Plaque Psoriasis
2019年7月5日 更新者:Thync Global, Inc.
Multicenter, Randomized, Double-Blind, Sham-Controlled, Efficacy and Safety Study of Autonomic Nerve Modulation (ANM) in Subjects With Moderate Plaque Psoriasis
This is a 16-week, prospective, multicenter, double-blind, controlled, randomized study assessing change in psoriasis severity and level of stress in patients with moderate psoriasis treated with ANM.
Psoriasis severity and stress levels will be measured at Weeks 0, 2, 8, 12, and 16.
研究概览
地位
未知
条件
研究类型
介入性
注册 (实际的)
110
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
California
-
Fremont、California、美国、94538
- Site 1
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Outpatient, male or female of any race, 18 years of age or older. This study has no pregnancy restrictions.
- BSA* <10% (excluding palms, soles, intertriginous and inverse areas).
- sPGA* ≥3 (NOTE: sPGA score will be averaged across all lesions as opposed to grading target lesions).
- BSA x sPGA ≥12.
- Subject diagnosed with chronic plaque psoriasis at least 6 months prior to screening.
- Treatment-naïve of prohibited biological immunomodulating agents at the time of screening, or decided to stop treatment with the biologic before screening for the study.
- Be able to follow study instructions and likely to complete all required visits.
- Sign the IRB-approved ICF (which includes HIPAA).
Exclusion Criteria:
- Non-plaque psoriasis (erythrodermic or pustular), guttate, inverse psoriatic arthritis, or drug-induced psoriasis.
- Subjects with plaque psoriasis on palms and soles at enrolment.
- Subjects with plaque psoriasis on the back of the neck that would interfere with device placement.
- Evidence of skin conditions other than psoriasis that would interfere with study-related evaluations of psoriasis.
- Other than psoriasis, history of any clinically significant (as determined by Investigator) or other major uncontrolled disease.
- Psoriasis flare or rebound within 4 weeks of Visit 1 or spontaneously improving or rapidly deteriorating plaque psoriasis during that same time period, as determined by investigator.
Use of prohibited medications within the following washout periods:
- Biological immunomodulating agents within the prior 12 weeks: etanercept (Enbrel), adalimumab (Humira), infliximab (Remicade), certolizumab pegol (Cimzia), ixekizumab (Taltz)
- Biological immunomodulating agents within the prior 24 weeks: ustekinumab (Stelara), secukinumab (Cosentyx), guselkumba (Tremfaya)
- Oral drugs within the prior 4 weeks: apremilast, methotrexate, cyclosporine, corticosteroids
- Oral drugs within the prior 12 weeks: acitretin
- Photochemotherapy (PUVA) within the prior 4 weeks
- Phototherapy (UVA/UVB) within the prior 2 weeks
- Topical treatment likely to impact signs and symptoms of psoriasis (e.g., corticosteroids, vitamin D analogues, retinoids, calcineurin inhibitors, salicylic acid, lactic acid, tar, urea, etc.) within the prior 2 weeks
- Prolonged sun exposure or use of tanning booths or other source of UV radiation.
- Medical or psychiatric conditions that may increase the risk associated with study participation or may interfere with the interpretation of study results or compliance of the subject and, in the opinion of the PI, would make the subject inappropriate for entry into this study.
- Clinically significant alcohol or drug abuse, or history of poor cooperation or unreliability.
- Exposure to any other investigational drug/device within 30 days prior to study entry.
- Subjects with a pacemaker, or any type of metal implant in the neck (i.e., T5 and above).
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
有源比较器:Active Treatment
Active stimulation pulsed current delivered over 15 minutes.
|
Thync ANM is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck.
|
假比较器:Control Treatment
Active stimulation pulsed current (alternative frequency) delivered over 15 minutes.
|
Thync ANM is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
BSA x sPGA average percent change from Baseline
大体时间:Week 16
|
Body Surface Area x Static Physician Global Assessment
|
Week 16
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
sPGA change from Baseline
大体时间:Week 16
|
Static Physician Global Assessment
|
Week 16
|
BSA change from Baseline
大体时间:Week 16
|
Body Surface Area
|
Week 16
|
Mean PASI change from Baseline
大体时间:Week 16
|
Psoriasis Area and Severity Index
|
Week 16
|
PASI 50
大体时间:Week 16
|
Psoriasis Area and Severity Index - 50% reduction
|
Week 16
|
PASI 75
大体时间:Week 16
|
Psoriasis Area and Severity Index - 75% reduction
|
Week 16
|
PSSI change from Baseline
大体时间:Week 16
|
Psoriasis Scalp Severity Index
|
Week 16
|
QVAS change from Baseline
大体时间:Week 16
|
Stress Level Quantified Visual Analogue Scale
|
Week 16
|
DLQI change from Baseline
大体时间:Week 16
|
Dermatology Life Quality Index
|
Week 16
|
PQOL-12 change from Baseline
大体时间:Week 16
|
Psoriasis Quality of Life - 12 Item
|
Week 16
|
HADS change from Baseline
大体时间:Week 16
|
Hospital Anxiety and Depression Scale
|
Week 16
|
Pruritus NRS change from Baseline
大体时间:Week 16
|
Pruritus Numerical Rating Scale
|
Week 16
|
Pruritus NRS responder rate (i.e., proportion of subjects achieving a ≥4-point improvement)
大体时间:Week 16
|
Pruritus Numerical Rating Scale
|
Week 16
|
TSQM
大体时间:Week 16
|
Treatment Satisfaction Questionnaire for Medication
|
Week 16
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
---|---|---|
sPGA responder rate (i.e., proportion of subjects achieving sPGA 0 or 1)
大体时间:Week 16
|
Static Physician Global Assessment
|
Week 16
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2018年10月2日
初级完成 (预期的)
2019年10月30日
研究完成 (预期的)
2019年10月30日
研究注册日期
首次提交
2019年1月23日
首先提交符合 QC 标准的
2019年1月23日
首次发布 (实际的)
2019年1月25日
研究记录更新
最后更新发布 (实际的)
2019年7月9日
上次提交的符合 QC 标准的更新
2019年7月5日
最后验证
2019年7月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.